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Abstract
Background: The ability to reduce inflammation in overweight and obese individuals may be
valuable in preventing the progression to metabolic syndrome with associated risks for heart
disease and diabetes. The purpose of this study was to evaluate the effect of multiple dosages of a
proprietary Mangosteen Juice blend on indicators of inflammation and antioxidant levels in obese
patients with elevated C-reactive protein (CRP) levels.
Methods: The study was an 8 week randomized, double-blind, placebo-controlled study with a
pre-study 2 week washout period. The study included four groups including placebo and three
difference doses of the test product, XanGo Juice™: 3, 6 or 9 oz twice daily. The primary outcome
measure of this study was high-sensitivity (HS)-CRP. Secondary outcome measures included other
biochemical indicators of inflammation, anthropomorphic measures and a safety evaluation.
Results:  One hundred twenty two (122) persons were screened for the study, 44 were
randomized and 40 completed the study. HS-CRP measurements dropped after 8 weeks treatment
compared to baseline in all 3 dose groups and increased in the placebo group. The changes from
baseline were not significant but the comparison of change from baseline was significant for the 18
oz group when compared to placebo (p = 0.02). Other markers of inflammation (inflammatory
cytokines) and a marker for lipid peroxidation (F2 isoprostane) did not show any significant
differences when compared with placebo. There was a trend towards a decrease in BMI in the juice
groups. There were no side effects reported in any of the groups and none of the laboratory or
EKG safety assessments indicated clinically significant changes for any subject.
Conclusion:  In this pilot, dose-finding study, a proprietary mangosteen juice blend (XanGo
Juice™) reduced CRP levels (increased change from baseline) compared to placebo for those
taking the highest dose of 18 oz per day. Further studies with a larger population are required to
confirm and further define the benefits of this juice. The juice was administered safely.
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Background
Obesity is a complex and difficult disorder which is multi-
factorial in its etiology. Central adipose tissue is known to
produce adiponectin, which plays a role in the glucose/
insulin axis as well as the production of inflammatory
cytokines. When central adipose tissue expands through
increased fat deposition, it appears that there is a concom-
itant drop in the production of adiponectin along with a
rise in the expression of inflammatory cytokines and C-
reactive protein (CRP) [1]. Inflammation is emerging as a
predictor of cardiovascular disease and may be considered
a precursor of metabolic syndrome. Therefore the ability
to reduce inflammation (as measured by CRP) in over-
weight and obese individuals may be valuable in prevent-
ing the progression to diabetes [2,3] and heart disease [4-
10]. Inflammation has also been implicated in lung dis-
ease [11-13], diseases of the digestive tract [14], skin dis-
eases [15-18], and arthritis [19-24].
There are many options in the treatment of inflammation.
Steroids have been used, but are best in acute inflamma-
tory presentation as there are potential side effects from
long term use, including poor resistance to infection.
Often inflammation is treated initially with nonsteroidal
inflammatory drugs (NSAIDS) such as ibuprofen,
naproxen and aspirin [24]. However, these drugs also
have potential side effects such as gastrointestinal bleed-
ing. A series of cyclooxygenase (COX)-2 inhibitors have
been marketed in recent years, but they too have had
issues related to side effects that require monitoring
[24,25]. These issues were the impetus for investigation of
traditional medical (Ayurveda and Traditional Chinese
Medicine) herbal products which may offer products that
have anti-inflammatory benefit with a lower risk-profile
[26].
Mangosteen fruits, Garcinia mangostana L. [Guttiferae],
were mentioned in Chinese medicinal records dating back
to the Ming dynasty (1360 to 1644 AD). Alpha- and γ-
mangostins from G. mangostana are identified as bioactive
substances with anti-inflammatory effects [27]. The anti-
inflammatory mechanism appears to be inhibition of the
conversion of arachadonic acid to prostaglandin (PG)E2
by COX [28,29] and blocking of inhibitor kappa-B kinase
(IKK) activity. IKK prevents nuclear factor kappa B (NFκB)
dependent COX-2 gene transcription [30]. In addition,
the  γ-mangostin xanthone has been shown to inhibit
lipopolysaccharide (LPS) induced activation of IKK, NFκB
and human COX-2 gene promoter region dependent tran-
scription, but had no effect on COX-1 [31]. Anti-inflam-
matory activity was also demonstrated in-vivo with γ-
mangostin using the rat paw edema model [31].
XanGo Juice™ contains a whole fruit puree of the mangos-
teen in addition to other fruit juices. The purpose of this
study was to evaluate the efficacy of multiple dosages of
XanGo Juice compared with placebo in the improvement
of inflammation and antioxidant levels in obese patients
with elevated CRP levels.
Methods
Study Design
The study was an 8 week randomized, double-blind, pla-
cebo-controlled study with a pre-study 2 week washout
period. The study was conducted at a single site: Medicus
Research, LLC, in Northridge, Ca. Sample size was not cal-
culated as this was an exploratory trial to compare three
concentrations of the target product to placebo. The study
was approved by the Copernicus Group IRB (Cary, NC)
prior to the initiation the study.
Recruitment
Subjects were serially recruited if they were between 30-75
years of age, had a body mass index (BMI) ≥ 30 and ≤ 45
kg/m2 (obese), a HS-CRP of ≥ 3, agreed to discontinue
anti-inflammatory medications and supplements (other
than daily 81 mg aspirin which was allowed), agreed to
use approved birth control methods if a female of child-
bearing age, and agreed to not initiate or change any exer-
cise or diet programs during the study. Subjects were
excluded if they had consumed the test product in the
past, had allergies to the test product, using any drugs that
can affect CRP, were taking hormone replacements, anti-
coagulant or anti-platelet therapy, had surgery in the past
6 months, smoked cigarettes, known alcohol or drug
abuse, had major systemic, inflammatory or chronic dis-
ease, untreated depression, active eating disorder, were
unable to understand or follow study protocol, were preg-
nant or lactating and had any medical condition which in
the opinion of the investigator might interfere with the
subject's ability in the trial.
Clinical Study Process
The subjects in the study came to the research clinic for a
total of 4 visits (V0-V3). At (V0), the screening visit, sub-
jects were screened for eligibility according to the inclu-
sion/exclusion criteria. Subjects gave their informed
written consent before any procedures were conducted.
There was a 2 week washout phase between screening and
enrollment during which subjects were asked to refrain
from consuming dietary supplements (including anti-oxi-
dants) and anti-inflammatory medications. The baseline
visit (V1) took place after the washout period with sub-
jects in a fasted state (10 hours). During this visit, the sub-
jects underwent a physical examination, had their blood
drawn and were randomized into groups. The laboratory
tests and procedures included HS-CRP and a cytokine
panel via Sandwich Immunoassay (Panomics, Inc., San
Diego, CA), Urine F2 isoprostane (Kronos Science Labora-
tory, Phoenix, AZ), and safety laboratory assessments
including complete blood count (CBC), comprehensive
metabolic panel (CMP), and urinalysis (Primex Labs,Nutrition Journal 2009, 8:48 http://www.nutritionj.com/content/8/1/48
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Northridge, CA) and platelet aggregometry (Platelet-
works, Helena Laboratories, Beaumont, TX). These lab
tests were repeated at the 4 week (V2) and 8 week (V3) vis-
its. An EKG was performed at baseline (V1) and again at 8
weeks (V3). During all 4 visits, anthropomorphic meas-
ures (hip and waist measurements, and weight) were
obtained and vital signs (blood pressure, temperature,
pulse, and respiration) were checked. Adverse event mon-
itoring was performed at each visit using a standardized
set of questions. Subjects were instructed not to change
their diet nor start any new exercise program during the
course of the study. In order to assess compliance, subjects
were required to return all unused investigational product
at each visit.
Outcome Measures
The primary outcome measure of this study was HS-CRP,
a marker of cardiac health related to inflammation. Sec-
ondary outcome measures were inflammatory cytokines,
urine F2 isoprostane (a measure of lipid peroxidation)
and anthropomorphic measures (weight, waist and hip
measurements, BMI, and body fat percentage). Safety
evaluations included CBC, CMP, EKG, urinalysis and
platelet aggregation, as well as particular attention to
potential gastrointestinal or cardiovascular related signals.
Randomization
Subjects were randomized using a table of random num-
bers derived from a random number generating program.
A simple randomization schema utilizing 4 groups was
given to the clinical staff. A single master sheet was used
to randomize subjects if they were eligible for inclusion in
the study following the clinical screen. The master sheet
included subject number, coordinator initials and date of
randomization was used to track the process and insure
no duplications of assignment. None of the clinical staff
had access to the assignment code key.
Product Description
The test product was XanGo Juice™ produced by XanGo,
LLC. The primary ingredient of XanGo Juice was mangos-
teen (Garcinia mangostana L.) whole fruit puree. XanGo
Juice also contained apple fruit juice, pear fruit juice,
grape fruit juice, pear fruit puree, blueberry fruit juice,
raspberry fruit juice, strawberry fruit juice, cranberry fruit
juice, and cherry fruit juice. The placebo consisted of
water, sucrose (3 g/30 ml), citric acid, red grape juice con-
centrate, fiber complex, grape skin, natural flavors, red
#40, cloud (ester gum), whey protein isolate, sodium ben-
zoate, xanthan gum, blue #1, and caramel color.
Three different dosages of the juice were tested and com-
pared to placebo. The product doses tested were 3 oz, 6 oz
and 9 oz. All doses and placebo were consumed in a total
of 9 oz of liquid in identical bottles. The placebo was used
to make up the volume for the lower doses. Subjects were
instructed to consume the assigned drink twice a day,
once in the morning and again in the evening. They there-
fore took a total of 0 to 18 oz of active product per day in
18 oz of fluid.
Data Management
The data from the field activity at the Northridge, CA. site
was received at the CRO facility of Medicus Research, LLC
in Midlothian, VA using password protected electronic
transfer. The Data Management staff logged in the data
files as they were received; code books were developed to
facilitate smooth and accurate editing and data entry. Stat-
istician and Data Analyst trained the data entry personnel
using the codebook as the guideline for instruction on
operational processes for this data. Data was analyzed
using paired sample t-tests for within subject means com-
parisons, independent sample t-tests for between group
comparisons (Placebo vs. each of the active groups indi-
vidually), t-tests of difference scores for both within and
between group comparisons (Placebo vs. each of the
active groups individually).
Data was analyzed with the CRO team continuing the
'blinded' structures concerning group assignment. The
analysis team only had the Placebo group identified to
them so that they would know how to organize the statis-
tical comparisons. Only after the analysis was completed
was the 'blind' broken in order to properly report relation-
ships between the 3 different strengths of the product
being tested and placebo.
Excel 2003 (Microsoft Corp, Redmond WA), was used for
data entry, validation, restructuring, calculating changes
in variables over time, reorganizing and reformatting
results, and preparing graphs. Statistical analyses (descrip-
tive statistics and means comparison tests, both within
and between group, were performed using SPSS Base Sys-
tem ver. 16 (SPSS Inc., Chicago IL.)
Results
One hundred twenty two persons were screened for the
study, 44 were randomized and 40 completed the study.
Two subjects withdrew from the study due to family
related issues, and two subjects were administratively
withdrawn for noncompliance. The groups were not sig-
nificantly different at baseline on age, gender, CRP, BMI,
or percentage body fat (Table 1). List wise deletion was
utilized in the analysis of study data as each of the 4
groups had a sample size of less than 20.
Outcome Measures
HS-CRP
Mean HS-CRP measurements dropped after 8 weeks treat-
ment compared to baseline in all 3 juice product dose
groups (Figure 1). In contrast, HS-CRP measurements
increased in the placebo group. None of the changes fromNutrition Journal 2009, 8:48 http://www.nutritionj.com/content/8/1/48
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baseline nor the between group comparisons at each time
point were significantly different (Table 2). However the
comparison of change from baseline to 8 weeks between
the 18 oz group and the placebo group was significant (p
= 0.019).
Inflammatory Cytokines
Epithelial Cell-Derived Neutrophil-Activating Protein (ENA)-78
There were no significant between group differences in
ENA-78 for the 6 and 18 oz groups. There was a significant
differences between placebo and the 12 oz group at base-
line (p = 0.002) and this difference continued for visits at
4 (p = 0.002) and 8 weeks (p = 0.022).
Human Interferon-Inducible Protein 10 (IP-10)
A comparison of the 6 oz juice to placebo for IP-10 found
a difference only at 8 weeks, with lower levels in the pla-
cebo group (p = 0.001). There was no significant compar-
ative change from baseline for these two groups. A
comparison of the 12 oz juice to placebo indicated no sig-
nificant differences between groups except for the change
from baseline to the 8 week visit (p = 0.029). The compar-
ison between the 18 oz group to placebo resulted in a sig-
nificant difference between the groups at the 8 weeks visit,
with lower levels in the placebo group (p = 0.016).
Interleukin (IL)-12p70
Between group comparisons IL-12p70 resulted in signifi-
cant differences for all three juice doses in comparison to
placebo at 8 weeks. Levels of IL-12p70 were comparatively
decreased in all juice groups; 6 oz (p = 0.0420, 12 oz (p =
0.0120 and 18 oz (p = 0.006)
Platelet Derived Growth Factor (PDGF)-BB
There were no significant differences for PDGF-BB com-
pared to placebo groups at any measurement point for the
6 oz, 12 oz, or 18 oz groups. There were also no significant
comparative changes between baseline and 8 weeks.
CCL-5
There were no significant differences between groups for
CCL5 (also known as RANTES: Regulated upon Activation,
Normal T-Cell Expressed and Secreted) at any measurement
points for the juice groups in comparison to placebo.
There was a significant comparative change from baseline
to 8 weeks for the 12 oz group (p = 0.027). In that case
there was a comparative reduction in the 12 oz juice
group.
Macrophage Inflammatory Protein-1 Beta (MIP-1 beta)
There were no significant differences compared to placebo
for MIP-1 beta at any measurement point for the 6 oz or
Table 1: Baseline Demographics
6 oz Xango 12 oz Xango 18 oz Xango Placebo
N 11 12 9 8
Male 10 1 0
Female 10 12 8 8
Age 52 33 50 45
BMI 33.7 32.6 34.1 34.8
Body Fat % 41.5 39.3 37.8 39.3
Baseline characteristics of the 40 subjects who completed the study, by study group. Means are given for age, CRP levels, BMI and percentage body 
fat.
HS-CRP Figure 1
HS-CRP. Mean HS-CRP values at baseline (V1) and 8 weeks 
(V3) for all 4 groups. None of the changes from baseline nor 
the between group comparisons at each time point were sig-
nificantly different. However the comparison of change from 
baseline to 8 weeks between the 18 oz group and the pla-
cebo group was significant (p = 0.019).
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Table 2: HS-CRP
Group Baseline 8 weeks Change
Placebo 13.10 ± 5.2 14.00 ± 8.5 + 0.90 ± 9.5
6 oz Xango 21.30 ± 16.8 14.65 ± 8.8 - 6.65 ± 11.7
12 oz Xango 18.33 ± 9.0 11.67 ± 4.2 - 6.66 ± 5.8
18 oz Xango 12.00 ± 5.6 10.67 ± 5.6 -1.33 ± 3.0
Mean HS-CRP levels plus/minus standard deviations at baseline, after 
8 weeks and the change over time. None of the changes from baseline 
were statistically significant. However the comparison of change from 
baseline to 8 weeks between the 18 oz group and the placebo group 
was significant (p = 0.019).Nutrition Journal 2009, 8:48 http://www.nutritionj.com/content/8/1/48
Page 5 of 7
(page number not for citation purposes)
12 oz groups. The 18 oz group showed a difference
between baseline and 8 week visit, with a reduced meas-
urement for the placebo group (p = 0.040).
Lipid Peroxidation
Lipid peroxidation was measured via F2 isoprostane levels
in the urine, normalized for urine creatinine. When nor-
malized, there were no significant changes from baseline,
nor any significant differences between the 3 different
dose groups compared with the placebo group at 8 weeks.
BMI and Body Fat Measurements
The results for BMI are presented in Figure 2 and those for
body fat analysis in Figure 3. For subjects in the 6 oz juice
group, there were no significant differences in BMI com-
pared to placebo at baseline or at the 4 week visit. How-
ever, at the 8 week visit, there was a significant decrease in
the juice group (p = 0.006). For subjects in the 12 oz
group there was no significant difference in BMI from pla-
cebo at baseline and there was a significant decrease in
compared to the placebo group at 4 weeks and 8 weeks (p
= 0.005 for both comparisons). There was no difference in
BMI between the 18 oz group and placebo at any meas-
urement point.
Body fat percentages (BF) for subjects in the 6 oz juice
group were not significantly different when compared to
placebo at baseline or at 4 weeks. At 8 weeks, there was a
significant difference in mean BF with the active product
mean higher than the placebo group (p = 0.016). BF for
those in the 12 and 18 oz product groups were not signif-
icantly different from placebo at baseline, 4 weeks, or 8
week measurement periods.
Safety Analysis
There were no side effects reported in any of the 3 treat-
ment groups or in the placebo group. None of the labora-
tory or EKG safety assessments indicated clinically
significant changes for any subject.
Discussion
XanGo Juice demonstrated an ability to reduce inflamma-
tion (as measured by HS-CRP), at all 3 dosages while the
placebo group showed a small increase in the amount of
inflammation. When compared with placebo, the change
in HS-CRP over 8 weeks was significant in the 18 oz
XanGo Juice group, but not for the 6 oz and 12 oz groups.
This suggests a possible dose dependent effect, but must
be interpreted cautiously as the measurement variability
was greater in the lower dose groups.
Other markers of inflammation (inflammatory cytokines)
and a marker of lipid peroxidation (a potential indicator
of oxidative stress) did not show any clinically significant
differences for the juice groups when compared with pla-
cebo. There was an indication that XanGo Juice may assist
in weight loss as measured with the BMI and further test-
ing is needed to confirm this suggestion.
This study was limited by its small sample size. There were
40 subjects in the study and 4 groups, thus there were
approximately 10 subjects per group. The small sample
size decreases the likelihood that changes from baseline
will be significant and reduces the likelihood that
between group differences will be statistically significant.
In addition, the use of multiple comparisons in the anal-
BMI Figure 2
BMI. Mean BMI values at baseline (V1), 4 weeks (V2) and 8 
weeks (V3) for all 4 groups. There were no significant differ-
ences between groups at baseline. There were significant 
decreases compared to placebo for subjects in the 6 oz juice 
group at the 8 week visit (p = 0.006), for subjects in the 12 
oz group at 4 weeks and 8 weeks (p = 0.005 for both com-
parisons). There were no significant differences between the 
18 oz group and placebo at any time point.
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Body Fat Analysis Figure 3
Body Fat Analysis. Mean values of body fat percentages at 
baseline (V1), 4 weeks (V2) and 8 weeks (V3) for all 4 groups. 
The only significant difference between groups was between 
the 6 oz Juice group and placebo at 8 weeks with the active 
product mean lower than that for placebo group (p = 0.016).
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ysis of the study data increases the risk of statistical error
resulting in a false positive. The use of an ANOVA or
ANCOVA analysis, which would have been more appro-
priate to compare multiple groups, was precluded by the
small sample size and lack of a reliable covariant. There-
fore, the results of this pilot study should be interpreted as
trends to be confirmed with further investigations using a
larger sample size.
The XanGo Juice™ product was safe at all dosages tested.
There were no adverse events (clinical, laboratory, or vital
sign) attributed to the product during the course of the
study.
Conclusion
In this pilot, dose-finding study, a proprietary mangos-
teen juice blend (XanGo Juice) reduced CRP levels
(increased change from baseline) compared to placebo
for those taking the highest dose of 18 oz per day. Further
studies with a larger population are required to confirm
and further define the benefits of this juice. Longer studies
will be needed to explore the role of inflammation in the
reduction of the risk of cardiovascular disease and diabe-
tes.
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